Exeltis Turkey

What Exeltis Turkey does

Exeltis Turkey (Exeltis İlaç Sanayii ve Ticaret A.Ş.) is the Turkish branded pharmaceutical subsidiary of the Madrid-based Insud Pharma group, operating as the commercial arm of CHEMO in the Turkish market. The company develops, manufactures, and markets prescription pharmaceuticals, over-the-counter products, and food supplements across three primary therapeutic areas: women's health (contraception, vaginal infections, pregnancy support, menopausal symptoms), respiratory (asthma and COPD), and pain management (topical formulations for musculoskeletal conditions). Its marketed portfolio in Turkey includes 147+ medicines, with key brands such as Gynomax, Neo-Penotran, Drospera, Glindium, and Sulidin, alongside food supplements including Regenesis Max, Velbon, and Lady Ana.

The company's underlying technology base centers on proprietary drug delivery platforms developed at its R&D center, including LPS™ (Lipid Penetration System), Lamellar Penetration System, Microsponge System, transdermal patch formulations, orally dissolving films, and the Cleantex® purification process for Omega-3 supplements. Manufacturing is conducted at an EU GMP-certified facility in Çerkezköy Organized Industrial Zone spanning 34,000 m², with annual capacity of 35 million boxes of semi-solid dosage forms (creams, gels, liquid gels, ovules, suppositories). The facility has supplied finished products to 34 countries across 4 continents since receiving EU GMP certification in 2018, and also provides contract manufacturing services to third-party pharmaceutical companies.

Exeltis Turkey generates revenue through three streams: prescription pharmaceutical sales promoted via a 980+ field sales force detailing doctors and pharmacists; OTC and food supplement sales through pharmacy distribution channels to end consumers; and third-party contract manufacturing from the Çerkezköy facility. Pricing for prescription products is regulated by the Turkish Ministry of Health. The company is a privately held subsidiary with no public listing, and benefits from group-level R&D, industrial, and biotech capabilities through its parents Insud Pharma, CHEMO, and MABXIENCE.

Name

Exeltis Turkey

Legal name

Exeltis İlaç Sanayii ve Ticaret A.Ş

Website

https://exeltis.com.tr

Company type

Private

Founded year

2010

Operating status

Operating

Headcount range

101–250 employees

Short description

Exeltis Turkey is a private branded pharmaceutical subsidiary of Spain's Insud Pharma, manufacturing and marketing women's health, respiratory, and pain management prescription drugs, OTC products, and food supplements through a large field sales force and pharmacy distribution in Turkey and 34 export markets.

Ownership category

akta.pro rank

Headquarters

HQ city

Etiler, Istanbul

HQ country

Türkiye

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B and B2C

Offering type

Hardware or Manufacturing

Cost components

Personnel, Marketing or Sales, Operations, Technology or R&D, Supply Chain, Infrastructure, Others

Revenue model

1. Prescription Pharmaceuticals: Sale of prescription-only medicines across therapeutic areas including women's health (contraceptives, vaginal infections, endometriosis), respiratory (asthma, COPD), and pain management. Distributed through pharmacy network and prescribed by healthcare professionals.
2. Over-the-Counter (OTC) Products and Food Supplements: Sale of non-prescription health products including Regenesis Max (pregnancy supplement), Velbon (calcium/magnesium/D3), Lady Ana (menopausal support), Lady Vigor, and Magneral. Available directly through pharmacies to consumers.
3. Contract Manufacturing: Exeltis provides third-party (contract) manufacturing services from its EU GMP-certified Çerkezköy facility to other national and international pharmaceutical companies, producing semi-solid dosage forms.

Pricing tiers

Go-to-market motion3 records

Distribution channels4 records

Marketing channels6 records

Core offering

Exeltis Turkey develops, manufactures, and markets branded pharmaceutical products including prescription medicines, over-the-counter (OTC) products, and food supplements across women's health, respiratory, and pain management therapeutic areas. The company operates an EU GMP-certified manufacturing facility in Çerkezköy producing semi-solid dosage forms (creams, gels, liquid gels, ovules, suppositories) with 35 million box annual capacity, and distributes through a 980+ medical representative field sales force and pharmacy network across Turkey. It also provides contract manufacturing services to third-party pharmaceutical companies.

Product overview

Exeltis Turkey is a branded pharmaceutical company under the CHEMO/Insud Pharma group, specializing in the development, manufacturing, and marketing of pharmaceutical products and medical devices. The product portfolio spans multiple therapeutic areas including Women's Health (contraception, vaginal infections, endometriosis, polycystic ovary syndrome, premenstrual syndrome), Respiratory (asthma, COPD), Pain Management (topical treatments), and Food Supplements (pregnancy support, bone health). Key products include contraceptive medications (ZLYNDA, DROSPERA, DROSETİL, DESİRETT), vaginal infection treatments (GYNOMAX, NEO-PENOTRAN), respiratory medications (GLİNİUM, FLUDALT DUO), and pain relief products (SULİDİN). The company operates a manufacturing facility in Çerkezköy with EU GMP certification and exports to 34 countries across 4 continents.

Differentiator

Problem solved

Functional benefit

Brands

• Regenesis Max Plus: Natural support product with Omega 3, Vitamins, and Minerals for pregnancy and breastfeeding.
• Gynomax
• Neo-Penotran
• Glindium
• Suldin
• Lady Ana
• Velbon

Products and services

• Regenesis Max Plus Food supplement containing Omega-3, folic acid, vitamins and minerals in capsule form supporting pregnancy and breastfeeding nutritional needs.
• Magneral Tablet supplement containing 365 mg Magnesium for women's health.
• Lady Vigör Supplement containing 300 mg Trigonella foenum-graceum, 50 mg Ginkgo Biloba, and 0.575 mg Vitamin B6 for women's health support.
• Lady Ana Supplement containing 300 mg Primrose Oil, 42.5 mg Hops, 0.7 mg Vitamin B6, 5.625 mcg Vitamin K, and 2.5 mcg Vitamin D for menopausal symptom relief (hot flashes, night sweats, sleep disorders) and bone health support.
• Velbon Food supplement containing Calcium, Magnesium, and Vitamin D3 for bone health during pregnancy, menopause, and sports.
• Gynomax (and Gynomax XL) Vaginal ovule products for vaginal infections containing Tioconazole and Tinidazole (Gynomax) and an XL variant with added Lidocaine.
• Neo-Penotran (and Forte variants) Vaginal ovule products containing Metronidazole and Miconazole Nitrate in multiple strengths (Neo-Penotran, Neo-Penotran Forte, Neo-Penotran Forte L with Lidocaine) for vaginal infections.
• Miko-Penotran Vaginal ovule containing 1200 mg Miconazole Nitrate for vaginal fungal infections.
• Zlynda Oral contraceptive containing 4 mg Drospirenone in 28 film-coated tablet form.
• Ertes 72 Emergency oral contraceptive containing 1.5 mg Levonorgestrel in single tablet form.
• Drospera (28 and 84 Tablet) Oral contraceptive containing 3 mg Drospirenone and 0.02 mg Ethinylestradiol in 24+4 film-coated tablet regimen.
• Drosetil (21 and 63 Tablet) Oral contraceptive containing 3 mg Drospirenone and 0.03 mg Ethinylestradiol in 21 film-coated tablet regimen.
• Desirett Progestogen-only oral contraceptive containing 75 mcg Desogestrel.
• Dienille Oral contraceptive containing 2 mg Dienogest and 0.03 mg Ethinylestradiol.
• Dienomet Oral medication containing 2 mg Dienogest in 28 tablet form (progestogen-only).
• Leverette Oral contraceptive containing 0.15 mg Levonorgestrel and 0.03 mg Ethinylestradiol.
• Cybelle Oral contraceptive containing 0.100 mg Levonorgestrel and 0.02 mg Ethinylestradiol.
• Glindium (and Glindium Plus) Inhalation powder capsules for respiratory conditions (COPD) containing 50 mcg Glycopyrronium (Glindium) and combination 43 mcg Glycopyrronium plus 85 mcg Indacaterol (Glindium Plus).
• Fludalt Duo (50/250 and 50/500) Inhaled respiratory medication combining Salmeterol Xinafoate (72.50 mcg) and Fluticasone Propionate (250 mcg or 500 mcg) for asthma and COPD treatment.
• Tioumıt Inhalation product containing 18 mcg Tiotropium bromide monohydrate in 30 capsule/inhaler format for COPD treatment.
• Sulidin (Sulidin, Sulidin Plus, Thermo Sulidin) Topical pain management line including Sulidin (0.3 g Nimesulide gel, 30 g), Sulidin Plus (1% Nimesulide plus 5% Lidocaine liquid gel, 50 g), and Thermo Sulidin (1% Nimesulide plus 0.025% Capsaicin) for musculoskeletal pain relief.
• Iveraxiro (8 and 10 Tablet) Oral medication containing 3 mg Ivermectin in tablet form.
• Tuodapro Duo (30 and 90 Capsule) Oral medication containing 0.5 mg Dutasteride and 0.4 mg Tamsulosin Hydrochloride in hard capsule form.
• Gamakuil Oral medication containing 400 mg Fenprobamate in 40 film tablet form.
• Kortos (Cream and Suppository) Kortos cream (Bismuth Subgallate, Benzocaine, Benzalkonium Chloride, Hydrocortisone Acetate in 30 g tube) and Kortos Suppository (Hydrocortisone Acetate plus Polidocanol).
• Epdantoin Oral medication containing 100 mg Phenytoin Sodium in 100 tablet form.
• KUILIL Oral medication containing 200 mg Fenprobamate and 200 mg Paracetamol.
• Contract Manufacturing Services (Semi-Solid Dosage Forms) Third-party contract manufacturing of semi-solid pharmaceutical dosage forms (creams, gels, liquid gels, ovules, suppositories) at the EU GMP-certified Çerkezköy facility, provided to other national and international pharmaceutical companies.

Quantifiable outcome

• 17 centers, 570 randomized patients, 440 completed patients in Phase 3 clinical study for antimicrobial combination therapy
• +1 more outcomes

Named customers2 records

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

Nine partnerships are on record, tiered core and minor.

• Mundo Sano FoundationcoreStrategic or Co-development PartnerMundo Sano is a non-profit foundation created by the CHEMO/Insud Pharma group, focused on changing the course of neglected diseases (Chagas, geo-parasitism, dengue, leishmaniasis, hydatidosis). Exeltis participates in Chemo's social responsibility through this foundation, which conducts multi-disciplinary scientific research with public-private partnerships in Argentina, Spain, and Ethiopia.
• Murcia Tropical Medicine Unit (UMT) / Hospital Virgen de ArrixacaminorStrategic or Co-development PartnerThe Tropical Medicine Unit at Hospital Virgen de Arrixaca, University of Murcia, works with Mundo Sano Foundation on Chagas disease elimination programs. This partnership has positioned Murcia as Spain's first autonomous region with a congenital Chagas elimination plan and one of the world's broadest diagnosis and treatment networks.
• ELEA-Phoenix Laboratory (Argentina)coreStrategic or Co-development PartnerIn 2010, when Benznidazole (Chagas medication) was in shortage, Mundo Sano joined with ELEA-Phoenix laboratory in Argentina and Insud Pharma in Spain to commence production first in Argentina and later in Spain. The medication is now distributed in 21 countries.
• International R&D Firms and UniversitiesminorStrategic or Co-development PartnerExeltis Turkey collaborates with international research and development firms and universities at various stages of new product development projects. These collaborations support innovation in drug delivery technologies and pharmaceutical formulation development.
• TÜBİTAK (The Scientific and Technological Research Council of Turkey)minorStrategic or Co-development PartnerExeltis Turkey R&D conducts multiple TÜBİTAK-supported projects in its pursuit of becoming a recognized R&D Center. These government-funded research collaborations support innovative pharmaceutical development.
• Insud Pharma (Parent Company)coreStrategic or Co-development PartnerInsud Pharma is the parent company of Exeltis, CHEMO, and MABXIENCE. Founded in 1977 and headquartered in Madrid, Spain, Insud Pharma operates in 40+ countries with 6,000+ employees. Exeltis represents the group's global sales and marketing operations, leveraging the group's R&D expertise (CHEMO) and biotech capabilities (MABXIENCE).
• CHEMO (Industrial Arm of Insud Pharma)coreStrategic or Co-development PartnerCHEMO serves as the industrial locomotive of the Insud Pharma group, responsible for R&D of pharmacological substances across multiple therapeutic areas. Exeltis benefits from CHEMO's research and development capabilities and product portfolio, including access to 300+ prescription medicines.
• Kariyer.netminorChannel Partner/ Reseller/ DistributorTurkish online recruitment platform used by Exeltis Turkey for posting job vacancies and managing job applications. Candidates can apply for open positions at Exeltis through this platform.
• LinkedInminorChannel Partner/ Reseller/ DistributorExeltis Turkey uses LinkedIn as a recruitment channel for posting open positions and attracting talent. The company maintains a LinkedIn company page for employer branding and talent acquisition.

Scale indicators10 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Theramex: Women's health specialty pharmaceutical company focused on contraception, menopause, and osteoporosis with portfolio overlap with Exeltis Turkey's women's health and bone health supplements business.
• Aenova: European CDMO with EU GMP-certified facilities specializing in solid and semi-solid dosage forms, including creams, gels, and suppositories. Direct comparable to Çerkezköy contract manufacturing services targeting similar international pharma clients.
• Recipharm: European CDMO with multiple EU GMP-certified sites offering contract manufacturing across multiple dosage forms including semi-solids. Competes for third-party pharmaceutical manufacturing contracts that Exeltis Turkey's Çerkezköy facility also targets.
• Gedeon Richter: Hungary-based pharmaceutical company with strong women's health franchise (contraception, menopause) and active presence in Turkish and CIS markets. Operates as both originator and generic manufacturer, similar to Exeltis Turkey's in-licensing + own-brand approach.
• Organon: Spun off from Merck in 2021 as a focused women's health company with franchises in contraception, fertility, and menopause. Directly comparable therapeutic area focus and similar product categories to Exeltis Turkey's women's health business.
• Bayer (Turkey): Global pharmaceutical division with major contraceptive brands (Yasmin, Yaz, Mirena) and women's health portfolio directly competing with Exeltis Turkey's contraception and reproductive health products through the same pharmacy and physician channels.

Broad incumbents

• Sandoz (Turkey): Global generic pharmaceutical leader and Novartis division operating in Turkey with broad generic portfolio. Competes on price in the off-patent molecule categories where many Exeltis Turkey products are positioned.
• Catalent: Global CDMO offering contract development and manufacturing services across softgel, oral solid, sterile, and biologic formats. Represents a broader competitive set in pharmaceutical contract manufacturing beyond Exeltis Turkey's semi-solid niche.

Regional players

• Abdi İbrahim: Largest Turkish pharmaceutical company with broad portfolio across multiple therapeutic areas, operating primarily in the same domestic market as Exeltis Turkey. Competes for the same physician detailing and pharmacy channel access.
• Eczacıbaşı Pharmaceuticals: Turkish conglomerate's pharmaceutical arm with consumer health and prescription products distributed through the same pharmacy channel as Exeltis Turkey. Competes particularly in food supplements and women's health categories.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks1 record

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/exeltis-turkey

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Exeltis Turkey